Adaptive Biotechnologies Corporation (ADPT) Stock Price & Analysis
Adaptive Biotechnologies Corporation (ADPT) closed at USD 25.58 on Thursday, October 15, 2026, down 0.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 25.62; the Oct 15, 2026 session ranged USD 24.92–25.91 on volume of 1,725,845 shares. Market capitalization is $4.08B, with a 52-week range of USD 12–30.74 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ADPT.md
Key facts (ADPT)
- 2 of 80 tracked superinvestors hold ADPT (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 29.81 (range 21–35).
- Total return with dividends: 1Y +48.1% vs S&P 500 +18.1%; 5Y -23.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.1, revenue estimate $71.6M.
Superinvestors (SEC 13F-HR, Q2 2026) (ADPT)
2 of 80 tracked investors hold ADPT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 1.83% | $643M | Unchanged |
| Polen Capital | Polen Capital Management | 0.02% | $2.2M | Reduced -11.7% |
Analysts (ADPT)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 29.81 (low 21, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $28 → $32 |
| 2026-10-13 | Morgan Stanley | Target raised | Equal-Weight | $22 → $27 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $25 → $32 |
| 2026-09-29 | Goldman Sachs | Initiated | Buy | $35 |
| 2026-09-22 | BTIG | Target raised | Buy | $25 → $34 |
| 2026-08-04 | Piper Sandler | Target raised | Overweight | $20 → $27.5 |
| 2026-07-30 | Morgan Stanley | Target raised | Equal-Weight | $20 → $22 |
| 2026-07-30 | TD Cowen | Target raised | Buy | $25 → $28 |
| 2026-07-30 | Guggenheim | Target raised | Buy | $22 → $25 |
| 2026-07-30 | BTIG | Target raised | Buy | $24 → $25 |
| 2026-07-09 | Morgan Stanley | Target raised | Equal-Weight | $18 → $20 |
| 2026-06-29 | Guggenheim | Target raised | Buy | $21 → $22 |
Total return (dividends reinvested) (ADPT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +48.1% | -23.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +48.3% | -5.2% |
| Volatility (annualized) | 67.1% | 72.7% |
| Max drawdown | -39.4% (Nov 2025→Mar 2026) | -93.5% (Nov 2021→Apr 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 25.58 |
|---|---|
| Change | ▼ 0.16% (down) |
| Previous Close | USD 25.62 |
| Open | USD 25.47 |
| Day Range | USD 24.92 – 25.91 |
| 52-Week Range | USD 12 – 30.74 |
| Volume | 1,725,845 shares |
| Market Cap | $4.08B |
| Exchange | NMS |
Technical Analysis (ADPT)
Nexqual's technical model rates ADPT "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.66 (neutral) |
| vs SMA50 | Below (USD 26.17) |
| MACD | -0.15 (negative) |
Analyst Ratings (ADPT)
Wall Street analysts rate ADPT "Buy" based on 9 analysts, with a mean price target of USD 29.81 (range USD 21–35), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 29.81 |
| High Target | USD 35 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (ADPT)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $71.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.25 vs est -0.13 ▼ miss |
| 2026-03-31 | USD -0.13 vs est -0.16 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.18 ▲ beat |
| 2025-09-30 | USD 0.06 vs est -0.14 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ADPT)
| Total Revenue | $308.08M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +21.50% |
| Gross Margin | +46.94% |
| Operating Margin | -22.04% |
| Profit Margin | -20.73% |
| ROE | -38.76% |
| Debt / Equity | 2.72 |
| Current Ratio | 4.8 |
| Total Cash | $344.26M |
| Total Debt | $410.50M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$48.95M (-17.7% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ADPT)
Nexqual rates Adaptive Biotechnologies Corporation's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +55% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 47%, operating -22% |
| Balance Sheet | Weak — $344M cash vs $410M debt |
| Cash Flow | Weak — FCF negative: -$49M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -39%, ROA -4.1% |
Ownership (ADPT)
| Insider Ownership | +1.29% |
|---|---|
| Institutional Ownership | +99.32% |
| Shares Outstanding | 159.60M |
| Float | 125.49M |
| Short % of Float | +9.38% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ADPT)
Adaptive Biotechnologies Corporation is led by Chad M. Robins (age 50), Co-Founder, CEO & Chairman, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, CEO & Chairman | Chad M. Robins (age 50) |
|---|---|
| President & COO | Julie Rubinstein (age 53) |
| VP, CFO & Principal Accounting Officer | Kyle Piskel (age 41) |
| Senior Vice President, Global Market & Business Development | Mary Pat Lancelotta |
Major Backers & Investors (ADPT)
Notable institutional backers of Adaptive Biotechnologies Corporation include Viking Global, Wellington Management, Shaw D.E. & Co., Inc., according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Viking Global | 18.79% |
| Wellington Management | 3.7% |
| Shaw D.E. & Co., Inc. | 2.9% |
| Westfield Capital Management Co LP | 2.67% |
| Invesco | 1.94% |
| ARK Invest | 1.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.85% |
| Vanguard Group | 12.45% |
| Geode Capital | 2.28% |
| State Street | 2.17% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VCYT | Veracyte, Inc. | USD 44.39 | ▲ 2.97% |
| CDNA | CareDx, Inc. | USD 66.68 | ▲ 1.9% |
| BLLN | BillionToOne, Inc. | USD 102.73 | ▲ 8.78% |
| SHC | Sotera Health Company | USD 18.07 | ▼ 0.77% |
| RDNT | RadNet, Inc. | USD 70.41 | ▼ 1.54% |
| GRAL | GRAIL, Inc. | USD 135.46 | ▼ 3.48% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt